There have been several recent regulatory updates related to cybersecurity in health care.
"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.
Improvements in technology have renewed interest in the technique.
"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Interest in AI in prostate cancer pathology has picked up speed since initial attempts of computer-aided diagnosis of the disease more than a decade ago, according to Peter A. Humphrey, MD, PhD.
Drs Smith and Helfand look ahead and provide their thoughts on future directions in the treatment of patients with prostate cancer.
"The most important thing I feel I've learned in my life so far is the value of human interaction and human connection," says Mark S. Litwin, MD, MPH.
Looking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Data showed a link between counties with higher rectal spacer use and a lower prevalence of ED at 4 to 5 years.
Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer (nmCRPC) show darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.
In the world of health care, factors such as remote care, complex IT environments, and connected health care devices are creating new avenues for cybercriminals to target.
Research indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.
“I think the great thing about Cost Plus Drugs is that, as we mentioned, it's simple, but it's also price transparent," says Raymond Xu, MD.
Fear of discrimination has downstream effects on health care.
Discover groundbreaking insights in urology as Larry Lipshultz, MD, shares innovative research and strategies for male fertility challenges.
“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD.
“Responsible application of AI is crucial, especially when the health and well being of people are at stake,” writes industry expert Manny Krakaris.
Industry expert provides in-depth advice.
In this article, an expert addresses the most common issues that come up with patients that may make them harder to deal with and solutions that may help a provider.
Growing evidence supports the existence of an intermediate metastatic disease state.
Many of the medications used in the treatment of ED have interactions with other medications, so it is crucial to carefully examine patient profiles to optimize therapy and ensure safety.
"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.
Panelists conclude their discussion by reflecting on key learnings and sharing advice for patient-centric management in overactive bladder (OAB) treatment, specifically focusing on effective communication and overlooked aspects of patient care. They offer guidance to other providers on enhancing patient experiences, particularly with procedures like Botox. The episode wraps up with each expert sharing their final thoughts and anticipations for advancements in OAB treatment in 2024, highlighting their commitment to addressing patient needs in this evolving field.
Ambulatory surgery centers were evaluated based entirely on objective, risk-adjusted measures of their patients’ outcomes.
Recent data suggest that obesity may be a risk factor for increased pain on transperineal biopsy.
"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.